Determine whether MRI activity 6 months after treatment initiation in the Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study ( CHAMPS ) predicted progression to clinically definite multiple sclerosis ( CDMS ) over the subsequent 30 months in intramuscular interferon beta-1a ( IM IFN-1a ) - treated patients vs placebo-treated patients .